Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

Frank Qian,Matti A Rookus,Goska Leslie,Harvey A Risch,Mark H Greene,Cora M Aalfs,Muriel A Adank,Julian Adlard,Bjarni A Agnarsson,Munaza Ahmed,Kristiina Aittomäki,Irene L Andrulis,Norbert Arnold,Banu K Arun,Margreet G E M Ausems,Jacopo Azzollini,Daniel Barrowdale,Julian Barwell,Javier Benitez,Katarzyna Białkowska,Valérie Bonadona,Julika Borde,Ake Borg,Angela R Bradbury,Joan Brunet,Saundra S Buys,Trinidad Caldés,Maria A Caligo,Ian Campbell,Jonathan Carter,Jocelyne Chiquette,Wendy K Chung,Kathleen B M Claes,J Margriet Collée,Marie-Agnès Collonge-Rame,Fergus J Couch,Mary B Daly,Capucine Delnatte,Orland Diez,Susan M Domchek,Cecilia M Dorfling,Jacqueline Eason,Douglas F Easton,Ros Eeles,Christoph Engel,D Gareth Evans,Laurence Faivre,Lidia Feliubadaló,Lenka Foretova,Eitan Friedman,Debra Frost,Patricia A Ganz,Judy Garber,Vanesa Garcia-Barberan,Andrea Gehrig,Gord Glendon,Andrew K Godwin,Encarna B Gómez Garcia,Ute Hamann,Jan Hauke,John L Hopper,Peter J Hulick,Evgeny N Imyanitov,Claudine Isaacs,Louise Izatt,Anna Jakubowska,Ramunas Janavicius,Esther M John,Beth Y Karlan,Carolien M Kets,Yael Laitman,Conxi Lázaro,Dominique Leroux,Jenny Lester,Fabienne Lesueur,Jennifer T Loud,Jan Lubiński,Alicja Łukomska,Lesley McGuffog,Noura Mebirouk,Hanne E J Meijers-Heijboer,Alfons Meindl,Austin Miller,Marco Montagna,Thea M Mooij,Emmanuelle Mouret-Fourme,Katherine L Nathanson,Bita Nehoray,Susan L Neuhausen,Heli Nevanlinna,Finn C Nielsen,Kenneth Offit,Edith Olah,Kai-Ren Ong,Jan C Oosterwijk,Laura Ottini,Michael T Parsons,Paolo Peterlongo,Georg Pfeiler,Nisha Pradhan,Paolo Radice,Susan J Ramus,Johanna Rantala,Gad Rennert,Mark Robson,Gustavo C Rodriguez,Ritu Salani,Maren T Scheuner,Rita K Schmutzler,Payal D Shah,Lucy E Side,Jacques Simard,Christian F Singer,Doris Steinemann,Dominique Stoppa-Lyonnet,Yen Yen Tan,Manuel R Teixeira,Mary Beth Terry,Mads Thomassen,Marc Tischkowitz,Silvia Tognazzo,Amanda E Toland,Nadine Tung,Christi J van Asperen,Klaartje van Engelen,Elizabeth J van Rensburg,Laurence Venat-Bouvet,Jeroen Vierstraete,Gabriel Wagner,Lisa Walker,Jeffrey N Weitzel,Drakoulis Yannoukakos,KConFab Investigators,HEBON Investigators,GEMO Study Collaborators,EMBRACE Collaborators,Antonis C Antoniou,David E Goldgar,Olufunmilayo I Olopade,Georgia Chenevix-Trench,Timothy R Rebbeck,Dezheng Huo,CIMBA

DOI: https://doi.org/10.1038/s41416-019-0492-8

Abstract:Background: Height and body mass index (BMI) are associated with higher ovarian cancer risk in the general population, but whether such associations exist among BRCA1/2 mutation carriers is unknown. Methods: We applied a Mendelian randomisation approach to examine height/BMI with ovarian cancer risk using the Consortium of Investigators for the Modifiers of BRCA1/2 (CIMBA) data set, comprising 14,676 BRCA1 and 7912 BRCA2 mutation carriers, with 2923 ovarian cancer cases. We created a height genetic score (height-GS) using 586 height-associated variants and a BMI genetic score (BMI-GS) using 93 BMI-associated variants. Associations were assessed using weighted Cox models. Results: Observed height was not associated with ovarian cancer risk (hazard ratio [HR]: 1.07 per 10-cm increase in height, 95% confidence interval [CI]: 0.94-1.23). Height-GS showed similar results (HR = 1.02, 95% CI: 0.85-1.23). Higher BMI was significantly associated with increased risk in premenopausal women with HR = 1.25 (95% CI: 1.06-1.48) and HR = 1.59 (95% CI: 1.08-2.33) per 5-kg/m2 increase in observed and genetically determined BMI, respectively. No association was found for postmenopausal women. Interaction between menopausal status and BMI was significant (Pinteraction < 0.05). Conclusion: Our observation of a positive association between BMI and ovarian cancer risk in premenopausal BRCA1/2 mutation carriers is consistent with findings in the general population.